Dystrophin proteolysis: A potential target for MMP-2 and its prevention by ischemic preconditioning

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 307, Issue 1, 2014, Pages

  Buchholz, Bruno ^a   Perez, Virginia ^a   Siachoque, Nadezda ^a   Miksztowicz, Verónica ^b   Berg, Gabriela ^b   Rodríguez, Manuel ^a   Donato, Martín ^a   Gelpi, Ricardo J ^a  

^a University of Buenos Aires   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Dystrophin; Matrix metalloproteinase 2; Myocardial infarction

Indexed keywords

BETA DYSTROGLYCAN; CALPAIN; DOXYCYCLINE; DYSTROPHIN; GELATINASE A; LINSIDOMINE; MALONALDEHYDE; SPECTRIN; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TRICHLOROACETIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME RELEASE; ENZYME SUBSTRATE; EXPERIMENTAL RABBIT; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; ISCHEMIC PRECONDITIONING; LIPID PEROXIDATION; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMYELOCYTE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ZYMOGRAPHY; ANIMAL; METABOLISM; MYOCARDIAL REPERFUSION INJURY; PROCEDURES; RABBIT; TREATMENT OUTCOME;

ANIMALS; DYSTROPHIN; ISCHEMIC PRECONDITIONING; MALE; MATRIX METALLOPROTEINASE 2; MYOCARDIAL REPERFUSION INJURY; RABBITS; TREATMENT OUTCOME;

EID: 84903600200     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00242.2013     Document Type: Article

References (30)

1. Ali MA, Cho WJ, Hudson B, Kassiri Z, Granzier H, Schulz R. Titin is a target of matrix metalloproteinase-2: implications in myocardial ischemia/ reperfusion injury. Circulation 122: 2039-2047, 2010.
2. Ali MA, Schulz R. Activation of MMP-2 as a key event in oxidative stress injury to the heart. Front Biosci 14: 699-716, 2009.
3. Ali MA, Stepanko A, Fan X, Holt A, Schulz R. Calpain inhibitors exhibit matrix metalloproteinase-2 inhibitory activity. Biochem Biophys Res Commun 423: 1-5, 2012.
4. Armstrong SC, Latham CA, Shivell CL, Ganote CE. Ischemic loss of sarcolemmal dystrophin and spectrin: correlation with myocardial injury. J Mol Cell Cardiol 33: 1165-1179, 2001.
5. Campos EC, O'Connell JL, Malvestio LM, Romano MM, Ramos SG, Celes MR, Prado CM, Simões MV, Rossi MA. Calpain-mediated dystrophin disruption may be a potential structural culprit behind chronic doxorubicin-induced cardiomyopathy. Eur J Pharmacol 670: 541-553, 2011.
6. Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski MW, Schulz R. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 101: 1833-1839, 2000.
7. Chow AK, Cena J, El-Yazbi AF, Crawford BD, Holt A, Cho WJ, Daniel EE, Schulz R. Caveolin-1 inhibits matrix metalloproteinase-2 activity in the heart. J Mol Cell Cardiol 42: 896-901, 2007.
8. Coker M, Doscher M, Thomas C, Galis Z, Spinale FG. Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations. Am J Physiol Heart Circ Physiol 277: H777-H787, 1999.
9. Committee for the Update of the Guide for the Care and Use of Laboratory Animals. Veterinary care. In: Guide for the Care and Use of Laboratory Animals (8th ed.). Washington, DC: National Academies, 2010.
10. Ehmsen J, Poon E, Davies K. The dystrophin-associated protein complex. J Cell Sci 115: 2801-2803, 2002.
11. Hernando V, Inserte J, Sartório CL, Parra VM, Poncelas-Nozal M, García-Dorado D. Calpain translocation and activation as pharmacological targets during myocardial ischemia/reperfusion. J Mol Cell Cardiol 49: 271-279, 2010.
12. Kandasamy AD, Chow AK, Ali MA, Schulz R. Matrix metalloproteinase-2 and myocardial oxidative stress injury: beyond the matrix. Cardiovasc Res 85: 413-423, 2010.
13. Kawada T, Masui F, Tezuka A, Ebisawa T, Kumagai H, Nakazawa M, Toyo-Oka T. A novel scheme of dystrophin disruption for the progression of advanced heart failure. Biochim Biophys Acta 1751: 73-81, 2005.
14. Kido M, Otani H, Kyoi S, Sumida T, Fujiwara H, Okada T, Imamura H. Ischemic preconditioning-mediated restoration of membrane dystrophin during reperfusion correlates with protection against contraction-induced myocardial injury. Am J Physiol Heart Circ Physiol 287: H81-H90, 2004.
15. Kyoi S, Otani H, Sumida T, Okada T, Osako M, Imamura H, Kamihata H, Matsubara H, Iwasaka T. Loss of intracellular dystrophin: a potential mechanism for myocardial reperfusion injury. Circ J 67: 725-727, 2003.
16. Lalu MM, Csonka C, Giricz Z, Csont T, Schulz R, Ferdinandy P. Preconditioning decreases ischemia/reperfusion-induced release and activation of matrix metalloproteinase-2. Biochem Biophys Res Commun 296: 937-941, 2002.
17. Lindsey M, Wedin K, Brown MD, Keller C, Evans AJ, Smolen J, Burns AR, Rossen RD, Michael L, Entman M. Matrix-dependent mechanism of neutrophil-mediated release and activation of matrix metalloproteinase 9 in myocardial ischemia/reperfusion. Circulation 103: 2181-2187, 2001.
18. Prasan A, McCarron H, White M, McLennan S, Tchen A, Hambly B, Jeremy R. Duration of ischaemia determines matrix metalloproteinase-2 activation in the reperfused rabbit heart. Proteomics 2: 1204-1210, 2002.
19. Rodríguez M, Cai WJ, Kostin S, Lucchesi BR, Schaper J. Ischemia depletes dystrophin and inhibits protein synthesis in the canine heart: mechanisms of myocardial ischemic injury. J Mol Cell Cardiol 38: 723-733, 2005.
20. Sariahmetoglu M, Skrzypiec-Spring M, Youssef N, Jacob-Ferreira AL, Sawicka J, Holmes C, Sawicki G, Schulz R. Phosphorylation status of matrix metalloproteinase-2 in myocardial ischaemia-reperfusion injury. Heart 98: 656-662, 2012.
21. Sawicki G, Leon H, Sawicka J, Sariahmetoglu M, Schulze CJ, Scott PG, Szczesna-Cordary D, Schulz R. Degradation of myosin light chain in isolated rat hearts subjected to ischemia-reperfusion injury: a new intracellular target for matrix metalloproteinase-2. Circulation 112: 544-552, 2005.
22. Shang ZJ, Ethunandan M, Górecki DC, Brennan PA. Aberrant expression of β-dystroglycan may be due to processing by matrix metalloproteinases-2 and-9 in oral squamous cell carcinoma. Oral Oncol 44: 1139-1146, 2008.
23. Singh RB, Dandekar SP, Elimban V, Gupta SK, Dhalla NS. Role of proteases in the pathophysiology of cardiac disease. Mol Cell Biochem 263: 241-256, 2004.
24. Sung MM, Schulz CG, Wang W, Sawicki G, Bautista-López NL, Schulz R. Matrix metalloproteinase-2 degrades the cytoskeletal protein-actinin in peroxynitrite mediated myocardial injury. J Mol Cell Cardiol 43: 429-436, 2007.
25. Viappiani S, Nicolescu AC, Holt A, Sawicki G, Crawford BD, León H, van Mulligen T, Schulz R. Activation and modulation of 72kDa matrix metalloproteinase-2 by peroxynitrite and glutathione. Biochem Pharmacol 77: 826-834, 2009.
26. Wang GY, Bergman MR, Nguyen AP, Turcato S, Swigart PM, Rodrigo MC, Simpson PC, Karliner JS, Lovett DH, Baker AJ. Cardiac transgenic matrix metalloproteinase-2 expression directly induces impaired contractility. Cardiovasc Res 69: 688-696, 2006.
27. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 106: 1543-1549, 2002.
28. Xie Z, Singh M, Singh K. Differential regulation of matrix metalloproteinase-2 and-9 expression and activity in adult rat cardiac fibroblasts in response to interleukin-1β. J Biol Chem 279: 39513-39519, 2004.
29. Yang X, Cohen MV, Downey JM. Mechanism of cardioprotection by early ischemic preconditioning. Cardiovasc Drugs Ther 24: 225-234, 2010.
30. Yoshida H, Takahashi M, Koshimizu M, Tanonaka K, Oikawa R, Toyo-oka T, Takeo S. Decrease in sarcoglycans and dystrophin in failing heart following acute myocardial infarction. Cardiovasc Res 59: 419-427, 2003.